β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

Exclusion Criteria

• •Patients with metastatic disease, known prior to surgery.
• •Patients in whom metastatic disease is found at surgery will complete the intervention phase, followed for additional month for potential complications, and will exit the study to allow potential participation in further clinical trials.
• •Patients in whom surgical resection is planned without curative intent.
• •Patients with renal failure, measured by Creatinine level \>1.5
• •Patients with significant heart failure (NYH 3 or higher)
• •Patients with significant liver failure (known cirrhosis, Bilirubin level\>2)
• •Patients suffering from asthma
• •Patients with known allergy to one or more of the study medications
• •Patients with known allergy to any medication from the non-steroidal anti-inflammatory drug group.
• •Patients with diabetes (type 1 or 2).
• •Patients treated chronically with one or more of the study medications
• •Patients treated chronically with any type of Beta adrenergic blocker.
• •Patients treated chronically with any type of COX inhibitor.
• •Patients with second or third degree AV block.
• •Patients with sinus bradycardia (patients with heart rate of less than 50).
• •Patients with sick sinus syndrome.
• •Patients with Prinzmetal's angina
• •Patients with right sided heart failure owing to pulmonary hypertension.
• •Patients with significant cardiomegaly
• •Patients with (current) pheochromocytoma
• •Patients with chronic Digoxin treatment
• •Patients with active peptic disease
• •Patients with peripheral vascular disease
• •Patients with history or concomitant malignant disease of any type.
• •Patients who were treated with chemotherapy in the last 10 years for any reason besides neo-adjuvant therapy for rectal cancer within the last six months.
• •Pregnant woman.
• •Patients participating in any other clinical trial